GlaxoSmithKline
GlaxoSmithKline (GSK), the world's second largest pharmaceutical company, and Golden Helix, Inc. have collaborated to jointly develop functionality within Golden Helix HelixTree software setting the industry standard in genetics analysis. GSK is an early investor of Golden Helix and has licensed two of its recursive partitioning software patents to GHI. GlaxoSmithKline continues to provide ongoing input of their world-class statistical geneticists and clinical trials statisticians in addition to having a non-exclusive world-wide site license for HelixTree.
For more information about GlaxoSmithKline, visit http://www.gsk.com.